Skip to content

Study on the Priorities of Patients Admitted to Intensive Care

Study on the Priorities of Patients Admitted to Intensive Care

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07417592
Acronym
PRIOREA
Enrollment
100
Registered
2026-02-18
Start date
2026-02-15
Completion date
2027-11-14
Last updated
2026-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intensive Care Unit Syndrome

Brief summary

The goal of this observational study is to learn about the priorities of patients admitted to intensive care units (ICUs) who have a life-threatening condition, as well as the priorities assumed by their designated relatives and healthcare professionals (nurses, nursing assistants, ICU physicians, and general practitioners).

Interventions

None listed

Sponsors

University Hospital, Brest
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

for Patient: * Adult Patient * Estimated length of stay in intensive care exceeding 72 hours * No objection from the patient or the designated representative, if the patient is unable to consent to participate in the study Inclusion criteria for Designated representative: * Adult Person * No objection to participate in the study Inclusion criteria for Caregiver: • No objection to participate in the study

Exclusion criteria

: * Patients under legal protection (guardianship, conservatorship) * Pregnant or breastfeeding women * Disagreement among the patient's relatives regarding the designated representative.

Design outcomes

Primary

MeasureTime frameDescription
Agreement rate48 hoursAssessment of the consistency between the priorities of patients and/or those assumed by the referring person and the priorities assumed by caregivers (resuscitation team and attending physician, if possible).

Countries

France

Contacts

CONTACTThomas GARGADENNEC, MD
thomas.gargadennec@chu-brest.fr02 30 33 78 94

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 6, 2026